Author

Julia Marie Frischkorn

Goethe University Frankfurt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:protein folding & dynamics· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Benedict‐Tilman BergeriD· 2 shared Lewis ElsoniD· 2 shared Stefan KnappiD· 2 shared Susanne MülleriD· 2 shared Thomas HankeiD· 2 shared Amelie TjadeniD· 1 shared Andreas C. JoergeriD· 1 shared Andreas Kraemer· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Benedict‐Tilman BergerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryJournal of Medicinal ChemistryPeer-reviewedAug 18, 2026

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137

Athina Zerva, Nicolai D. Raig, Zaile Zhuang…·Thomas Hanke

The paper describes the development of AZ137, a potent and selective HIPK4 inhibitor derived from bosutinib, and validates its utility as a tool for studying HIPK4's biological functions.

1 citation

experimental assaydrug response / drug discovery

𝕏 PostBluesky

BiochemistryJournal of Medicinal ChemistryPeer-reviewedDec 21, 2023

Synthesis of pyrazole-based macrocycles leads to a highly selective inhibitor for MST3

Jennifer Alisa Amrhein, Lena M. Berger, Dimitrios-Ilias Balourdas…·Thomas Hanke

The paper designs and synthesizes a macrocyclic inhibitor, JA310, that selectively targets MST3 with high potency and kinome-wide selectivity.

18 citations

experimental assaydrug response / drug discovery

𝕏 PostBluesky